Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients

Journal of Thrombosis and Thrombolysis

Volumn 31, Issue 1, 2011, Pages 113-118

  You, Joyce H S ^b   Wong, Raymond S M ^a   Waye, Mary M Y ^a   Mu, Yawei ^a   Lim, Cadmon K ^a   Choi, Kai Chow ^a   Cheng, Gregory ^a  

^a Chinese University of Hong Kong   (Hong Kong)

^b NONE

Author keywords

Chinese; CYP2C9 genotype; Dosing algorithm; Pharmacogenetics; VKORC1 genotype; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; MENADIONE EPOXIDE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1 PROTEIN; VITAMIN K GROUP; WARFARIN;

ADULT; AGE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHINESE; CONTROLLED STUDY; DOSE CALCULATION; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; INTERVIEW; MAINTENANCE THERAPY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; VITAMIN INTAKE;

AGE FACTORS; AGED; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; BODY WEIGHT; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HONG KONG; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; VITAMIN K; VITAMINS; WARFARIN;

EID: 78651495631     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-010-0497-x     Document Type: Article

References (22)

1. HCM Yu TYK Chan JAJH Critchely KS Woo 1996 Factors determining the maintenance dose of warfarin in Chinese patients QJM 89 127 135 1:STN:280:DyaK28zgs1GksA%3D%3D 8729554
2. JHS You FWH Chan RSM Wong G Cheng 2005 Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol 59 582 587 1:CAS:528:DC%2BD2MXltFGgt7w%3D 10.1111/j.1365-2125.2005.02361.x 15842557
3. R Loebstein H Yonath D Peleg, et al. 2001 Interindividual variability in sensitivity to warfarin-nature or nuture? Clin Pharmacol Ther 70 159 164 1:CAS:528:DC%2BD3MXmslygs74%3D 10.1067/mcp.2001.117444 11503010
4. GP Aithal CP Day PJ Kesteven AK Daly 1999 Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications Lancet 353 717 719 1:STN:280:DyaK1M7ntFGhsQ%3D%3D 10.1016/S0140-6736(98)04474-2 10073515
5. MK Higashi DL Veenstra LM Kondo, et al. 2002 Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy JAMA 287 1690 1698 1:CAS:528:DC%2BD38XisFaru7c%3D 10.1001/jama.287.13.1690 11926893
6. J Taube D Halsall T Baglin 2000 Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment Blood 96 1816 1819 1:CAS:528: DC%2BD3cXmt1Omtbc%3D 10961881
7. G D'Andrea RL D'Ambrosio P Di Perna, et al. 2005 A polymorphism in the VKORC1 gene is associated with inter-individual variability in the dose-anticoagulant effect of warfarin Blood 105 645 649 10.1182/blood-2004-06- 2111 15358623
8. MJ Rieder AP Reiner BF Gage, et al. 2005 Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose N Engl J Med 352 2285 2293 1:CAS:528:DC%2BD2MXksl2ltrk%3D 10.1056/NEJMoa044503 15930419
9. DL Veenstra JHS You MJ Rieder, et al. 2005 Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population Pharmacogenet Genomics 15 687 691 1:CAS:528:DC%2BD2MXpslahtLc%3D 10.1097/01.fpc.0000174789.77614.68 16141794
10. L Miao J Yang 2007 Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients Eur J Clin Pharmacol 63 1135 1141 1:CAS:528:DC%2BD2sXht1yit7zM 10.1007/s00228-007-0381-6 17899045
11. SW Huang HS Chen XQ Wang, et al. 2009 Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients Pharmacogenet Genom 19 226 234 1:CAS:528:DC%2BD1MXjsVWqsbk%3D 10.1097/FPC.0b013e328326e0c7
12. SM Wen MTM Lee JJ Chen, et al. 2008 Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes Clin Pharmacol Ther 84 83 89 1:CAS:528:DC%2BD1cXnt1KqsL4%3D 10.1038/sj.clpt.6100453 18183038
13. 1 (phylloquinone) content of foods: a provisional tale J Food Compost Anal 6 100 120 10.1006/jfca.1993.1014
14. The International Warfarin Pharmacogenetics Consortium 2009 Estimation of the warfarin dose with clinical and pharmacogenetic data N Engl J Med 360 753 764 10.1056/NEJMoa0809329
15. M Wadelius 2009 Use of pharmacogenetics in guiding treatment with warfarin Clin Chem 55 709 711 1:CAS:528:DC%2BD1MXktVWqsLo%3D 10.1373/clinchem.2008.115964 19181736
16. MH Rosove WW Grody 2009 Should we be applying warfarin pharmacogenetics to clinical practice? No, not now Ann Intern Med 151 270 273 19687493
17. MH Eckman R Rosand SM Greenberg BF Gage 2009 Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with non-valvular atrial fibrillation Ann Intern Med 150 73 83 19153410
18. JHS You KKN Tsui RSM Wong G Cheng 2009 Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients initiating warfarin therapy Clin Pharmacol Ther 86 540 547 1:STN:280:DC%2BD1MjgtlKjtQ%3D%3D 10.1038/clpt.2009.104 19571807
19. EA Millican PA Lenzini PE Milligan, et al. 2007 Genetic-based dosing in orthopedic patients beginning warfarin therapy Blood 110 1511 1515 1:CAS:528:DC%2BD2sXhtVSgsb3N 10.1182/blood-2007-01-069609 17387222
20. AHB Wu P Wang A Smith, et al. 2008 Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations Pharmacogenomics 9 169 178 1:CAS:528:DC%2BD1cXht1SgtLg%3D 10.2217/14622416.9.2.169 18370846
21. JHS You FWH Chan RSM Wong G Cheng 2004 The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy-a decision analysis Thromb Haemost 92 590 597 1:CAS:528:DC%2BD2cXnvFyhtbw%3D 15351856
22. H Koertke A Zittermann G Tenderich, et al. 2007 Low-dose oral anticoagulation in patients with mechanical heart valve prostheses: final report from the early self-management anticoagulation trial II Eur Heart J 28 2479 2484 1:CAS:528:DC%2BD2sXhtlyrtbnL 10.1093/eurheartj/ehm391 17890730